Pfizer to depart GSK's ViiV as Shionogi doubles its stake

Pfizer is walking away from a specialist HIV company it created together with GSK more than a decade ago, with Shionogi taking its place. The Japanese drugmaker will buy about $2.13 billion worth of new ...